

# Lucia Moiola

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/628578/lucia-moiola-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131  
papers

3,579  
citations

34  
h-index

54  
g-index

137  
ext. papers

4,301  
ext. citations

5.6  
avg, IF

4.9  
L-index

#	Paper	IF	Citations
131	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	4
130	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	6
129	HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis.. <i>Neurological Sciences</i> , <b>2022</b> , 43, 2095	3.5	0
128	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , <b>2022</b> , 98, e1626-e1636	6.5	0
127	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 3634-3645	15.1	8
126	Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1374-1383	5	1
125	COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 3375-3383	6	33
124	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1520-1532	5	6
123	COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. <i>Journal of Neurology</i> , <b>2021</b> , 268, 2697-2699	5.5	6
122	Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. <i>Brain</i> , <b>2021</b> , 144, 848-862	11.2	3
121	Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports. <i>Neurological Sciences</i> , <b>2021</b> , 42, 9-13	3.5	1
120	Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?. <i>Journal of Neurology</i> , <b>2021</b> , 268, 3975-3979	5.5	1
119	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211023365	5	2
118	Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	21
117	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 52	4.9	4
116	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 21-34	4.3	4
115	In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. <i>Brain</i> , <b>2021</b> , 144, 186-197	11.2	9

114	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 347-359	5	24
113	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 331-346	5	16
112	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study. <i>Neurotherapeutics</i> , <b>2021</b> , 18, 878-888	6.4	2
111	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 89, 780-789	9.4	189
110	Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 89, 1011-1022	9.2	3
109	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211035318	5	21
108	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 1738-1744	5.3	36
107	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 42, 102145	4	2
106	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- $\beta$ in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 40, 101952	4	
105	Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 286-294	7.1	12
104	Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 409, 116603	3.2	16
103	Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. <i>Autoimmunity</i> , <b>2020</b> , 53, 21-27	3	5
102	Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100053	18	6
101	Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 418, 117104	3.2	1
100	Neuromyelitis optica and myotonic dystrophy type 2: a rare association with diagnostic implications. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2744-2746	5.5	1
99	Successful treatment of HIV-associated tumefactive demyelinating lesions with corticosteroids and cyclophosphamide: a case report. <i>Journal of Neurology</i> , <b>2020</b> , 267, 3773-3775	5.5	
98	Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1197-1206	5	21
97	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 208-217	6.4	16

96	Loss of Circulating CD8+ CD161 T Cells in Primary Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1922	8.4	5
95	Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. <i>Journal of Neurology</i> , <b>2019</b> , 266, 3163-3166	5.5	1
94	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 33, 75-77	4	8
93	Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5 year MRI study. <i>Neurology</i> , <b>2019</b> , 92, e1709-e1723	6.5	15
92	Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 1752-1761	2.3	5
91	In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. <i>Scientific Reports</i> , <b>2019</b> , 9, 10371	4.9	19
90	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e591	9.1	6
89	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , <b>2019</b> , 85, 606-610	9.4	23
88	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , <b>2019</b> , 92, e733-e741	6.5	30
87	Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 27, 403-405	4	14
86	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 28, 57-59	4	1
85	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 399-407	5	20
84	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , <b>2018</b> , 90, e823-e831	6.5	54
83	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , <b>2018</b> , 90, e832-e839	6.5	48
82	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. <i>Journal of Neurology</i> , <b>2018</b> , 265, 896-905	5.5	8
81	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 167-174	5	14
80	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , <b>2018</b> , 138, 447-453	3.8	2
79	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 384, 58-60	3.2	1

78	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2851-2860	5.5	24
77	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. <i>Neurological Sciences</i> , <b>2018</b> , 39, 1467-1470	3.5	6
76	Pharmacogenetic study of long-term response to interferon- $\beta$ treatment in multiple sclerosis. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 84-91	3.5	21
75	Dysregulation of MS risk genes and pathways at distinct stages of disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e337	9.1	19
74	Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 378, 233-237	3.2	9
73	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , <b>2017</b> , 136, 454-461	3.8	15
72	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , <b>2017</b> , 264, 1005-1007	5.1	2
71	To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , <b>2017</b> , 82, 697-705	9.4	30
70	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , <b>2017</b> , 89, 1265-1273	6.5	9
69	No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. <i>Neurology</i> , <b>2017</b> , 89, 2469-2475	6.5	27
68	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 383, 166-168	3.2	20
67	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2017</b> , 2,	0	3
66	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , <b>2017</b> , 38, 361-364	3.5	5
65	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. <i>CNS Drugs</i> , <b>2017</b> , 31, 33-50	6.7	39
64	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 628-40	5	20
63	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 511-9	5	64
62	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 292-301	5	13
61	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1506-1508	5	36

60	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1315-26	5	46
59	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , <b>2016</b> , 263, 1727-35	5.5	35
58	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1741-1749	5	19
57	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , <b>2016</b> , 13, 799-805	8	11
56	Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study. <i>Neurological Sciences</i> , <b>2016</b> , 37, 235-42	3.5	28
55	Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168376	3.7	35
54	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , <b>2016</b> , 8,	6.2	1
53	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , <b>2016</b> , 2016, 2303857	1.1	13
52	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , <b>2016</b> , 23, e39-40	6	1
51	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 361, 184-6	3.2	2
50	Recurrence of disease activity after repeated Natalizumab withdrawals. <i>Neurological Sciences</i> , <b>2015</b> , 36, 465-7	3.5	8
49	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 956-9	5	21
48	Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 973-80	6	13
47	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 289, 62-7	3.5	13
46	Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e129	9.1	14
45	Natalizumab in the pediatric MS population: results of the Italian registry. <i>BMC Neurology</i> , <b>2015</b> , 15, 174	3.1	58
44	The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective. <i>Multiple Sclerosis International</i> , <b>2015</b> , 2015, 353828	1.1	5
43	Myeloid cells as target of fingolimod action in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e157	9.1	18

42	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , <b>2014</b> , 35, 307-16	3.5	28
41	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 802-11	5	10
40	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , <b>2014</b> , 83, 1432-8	6.5	78
39	Subacute visual loss and bilateral fixed mydriasis: an atypical case of giant cell arteritis. <i>Neurological Sciences</i> , <b>2014</b> , 35, 1309-10	3.5	2
38	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , <b>2014</b> , 14, 114	3.1	22
37	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 520-6	4	30
36	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , <b>2014</b> , 75, 447-53	9.4	35
35	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 4180-92	5.9	34
34	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 845-50	5.5	48
33	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , <b>2014</b> , 82, 1314-21	6.5	40
32	Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 1342-7	5	47
31	Practice of yoga may cause damage of both sciatic nerves: a case report. <i>Neurological Sciences</i> , <b>2013</b> , 34, 393-6	3.5	16
30	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1074-83	5	72
29	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , <b>2013</b> , 34, 1633-7	3.5	17
28	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1106-12	5	50
27	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1533-8	5	79
26	Allogeneic Hematopoietic Stem Cell Transplantation For Severe Neuromyelitis Optica. <i>Blood</i> , <b>2013</b> , 122, 5539-5539	2.2	1
25	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , <b>2012</b> , 530, 155-60	3.3	11

24	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. <i>Neuroscience Letters</i> , <b>2012</b> , 508, 4-8	3.3	79
23	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , <b>2012</b> , 12, 124	3.1	72
22	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , <b>2012</b> , 12, 165	3.1	66
21	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 329-34	5	65
20	MGAT5 and disease severity in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2011</b> , 230, 143-7	3.5	7
19	Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 702-7	5	19
18	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1490-9	5	22
17	Brain macro- and microscopic damage in patients with paediatric MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 1357-62	5.5	17
16	Functional and structural connectivity of the motor network in pediatric and adult-onset relapsing-remitting multiple sclerosis. <i>Radiology</i> , <b>2010</b> , 254, 541-50	20.5	63
15	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , <b>2010</b> , 31, 467-70	3.5	36
14	Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 2844-51	5.9	57
13	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , <b>2009</b> , 30, 193-9	3.5	58
12	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1503-11	40	475
11	A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 1076-83	5	61
10	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. <i>Neurological Sciences</i> , <b>2007</b> , 28, 127-32	3.5	49
9	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , <b>2005</b> , 11, 420-4	5	90
8	Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study. <i>American Journal of Neuroradiology</i> , <b>2003</b> , 24, 249-53	4.4	36
7	IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. <i>European Journal of Immunology</i> , <b>1998</b> , 28, 2487-97	6.1	99

6	Interferon-gamma induces T lymphocyte proliferation in multiple sclerosis via a Ca(2+)-dependent mechanism. <i>Journal of Neuroimmunology</i> , <b>1995</b> , 62, 169-76	3.5	11
5	Gamma interferon activates a previously undescribed Ca <sup>2+</sup> influx in T lymphocytes from patients with multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 4825-9	11.5	26
4	Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4 <sup>+</sup> cells of myasthenia gravis patients and healthy subjects. <i>Journal of Clinical Investigation</i> , <b>1994</b> , 93, 1020-8	15.9	41
3	T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , <b>1993</b> , 681, 198-218	6.5	23
2	Myasthenia gravis. CD4 <sup>+</sup> T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor. <i>Journal of Clinical Investigation</i> , <b>1992</b> , 90, 1558-67	15.9	23
1	Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , <b>1990</b> , 30, 129-34	3.5	6